Sweden's AddLife beats Q2 sales estimates, margin improves
Sweden's AddLife beats Q2 sales estimates, margin improves
Overview
Sweden life science supplier's Q2 net sales rose 6% yr/yr, beating analyst expectations
Q2 EBITA up 11% and margin improved to 12.6%
Company says recent acquisitions contributed to earnings growth
Outlook
AddLife says recent acquisitions in H1 are expected to contribute annual net sales of about SEK 185 mln
AddLife is actively pursuing further acquisitions to support earnings growth
Result Drivers
ACQUISITIONS - Recent acquisitions made a significant contribution to earnings growth, according to CEO Fredrik Dalborg
IMPROVEMENT INITIATIVES - Company said ongoing improvement efforts are delivering stronger margins and increased cash flow
Company press release: ID:nMFN35rClY
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Sales | Beat | SEK 2.72 bln | SEK 2.68 bln (4 Analysts) |
Q2 EPS |
| SEK 1.06 |
|
Q2 Net Income |
| SEK 130 mln |
|
Q2 Adjusted Free Cash Flow |
| SEK 165 mln |
|
Q2 EBITA |
| SEK 342 mln |
|
Q2 EBITA Margin |
| 12.60% |
|
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for AddLife AB is SEK196.00, about 18.1% above its July 15 closing price of SEK165.90
The stock recently traded at 33 times the next 12-month earnings vs. a P/E of 29 three months ago
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)